Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
Shares of Dell Technologies rose about 2% after Lenovo reported that its AI server pipeline jumped 157% quarter over quarter to $54 billion, a data point investors linked to continued strength in the AI server supply chain.
THE APEX TIMES
THE APEX TIMES
A valuation snapshot places Costco in line with the best-performing names in its peer set, yet the underlying performance outlines appear mixed, with growth looking stronger than profitability.
THE APEX TIMES
The 20,000-square-foot facility, located inside Apple’s Houston manufacturing site, is designed to let small- and medium-sized companies and students practice smart-manufacturing techniques and learn processes used in Apple product production.
THE APEX TIMES
A new market-focused write-up argues Walmart’s e-commerce business is increasingly shaping its earnings profile, but the broader market may only be paying attention later in the year.
THE APEX TIMES
A Yahoo Finance market note points to Union Pacific’s shares looking closer to fairly valued once investors focus on cash flow, not just reported earnings, after a strong multi-year run.
THE APEX TIMES
A delay to Virgin Galactic’s planned commercial spaceflight start, originally targeted for the fourth quarter of 2026, has prompted Morgan Stanley to warn of elevated execution risk and the possibility of additional schedule slippage.
THE APEX TIMES
The company disclosed memorandums of understanding with major asset managers and lenders to support independent compute financing platforms, a move that could reshape how AI data center builds get funded and how Nvidia participates in that spend.
THE APEX TIMES
A widely discussed AI financing package aimed at turning compute into an investable market is drawing skepticism from some investors, who warn that even the biggest numbers on paper may not cover the pace of AI buildouts.
THE APEX TIMES
A new market argument says affordability pressures around GLP-1 therapies could ultimately expand Eli Lilly’s addressable market rather than cap it.
